Thanks Tada! A lower MACE rate for the placebo group that can be logically explained (as well quantatively of course), would tie up all the loose ends for me.  

In that case, it is even more impressive that while we missed the statistical significance, the RRR may still be high enough. To get even a 20% RRR on a patient group that has been already dosed so heavily?

So if the secondary end point targets are met and the bio markers go the right way, then the only knock against us would be the primary end points being statistically missed.  In the Seeking Alpha update, BKC notes that "If there is a statistically significant effect of a predefined endpoint, such as vascular dementia - the FDA will be very interested in it".  The kidney disease end point is where I have confidence, given Phase 2 data.